In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-associated Steatotic Liver Disease

被引:0
|
作者
Bao, Qinglan [1 ]
Zhang, Xiaoxiao [2 ]
Chen, Yingsong [1 ,3 ,4 ]
Wang, Tegexibaiyin [5 ]
Siqin, Bateer [6 ]
机构
[1] Inner Mongolia Med Univ, Hohhot, Peoples R China
[2] Xilin Gol League Mongolian Med Hosp, Xilingol Leagu, Peoples R China
[3] National&local Joint Mongolian Med R&D Engn Ctr, Tongliao, Peoples R China
[4] Inner Mongolia Minzu Univ, Tongliao, Peoples R China
[5] Affiliated Hosp Inner Mongolia Minzu Univ, Tongliao, Peoples R China
[6] Tradit Chinese & Mongolian Med Res Inst Inner Mong, Hohhot, Peoples R China
来源
关键词
ACID-INDUCED STEATOSIS; DIAGNOSIS; DIET;
D O I
10.3791/66810
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has surged due to changes in economic and lifestyle patterns, leading to significant health challenges. Previous reports have studied the establishment of animal and cellular models for MASLD, highlighting differences between them. In this study, a cellular model was created by inducing fat accumulation in MASLD. HepG2 cells were stimulated with the unsaturated fatty acid oleic acid at various concentrations (0.125 mM, 0.25 mM, 0.5 mM, 1 mM) to emulate MASLD. The model's efficacy was assessed using cell counting kit-8 assays, Oil Red O staining, and lipid content analysis. This study aimed to create a simple-to-operate cellular model for MASLD cells. Results from the cell counting kit-8 assays showed that the survival of HepG2 cells was dependent on the concentration of oleic acid, with a GI50 of 1.875 mM. Cell viability in the 0.5 mM and 1 mM groups were significantly lower than those in the control group (P < 0.05). Furthermore, Oil Red O staining and lipid content analysis examined fat deposition at varying oleic acid concentrations (0.125 mM, 0.25 mM, 0.5 mM, 1 mM) on HepG2 cells. The lipid content of the 0.25 mM, 0.5 mM, and 1 mM groups was significantly higher than that of the control group (P < 0.05). Additionally, triglyceride levels in the OA groups were significantly higher than those in the control group (P < 0.05).
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease
    Mak, Anne Linde
    Wassenaar, Nienke
    van Dijk, Anne-Marieke
    Troelstra, Marian
    Houttu, Veera
    van Son, Koen
    Driessen, Stan
    Zwirs, Diona
    van den Berg-Faay, Sandra
    Shumbayawonda, Elizabeth
    Runge, Jurgen
    Doukas, Michail
    Verheij, Joanne
    Beuers, Ulrich
    Nieuwdorp, Max
    Cahen, Djuna L.
    Nederveen, Aart
    Gurney-Champion, Oliver
    Holleboom, Adriaan
    JHEP REPORTS, 2024, 6 (03)
  • [2] Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ali, Sajjadh M. J.
    Lai, Michelle
    ANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : ITC1 - ITC17
  • [3] Metabolic dysfunction-associated steatotic liver disease and the heart
    Driessen, Stan
    Francque, Sven M.
    Anker, Stefan D.
    Cabezas, Manuel Castro
    Grobbee, Diederick E.
    Tushuizen, Maarten E.
    Holleboom, Adriaan G.
    HEPATOLOGY, 2023,
  • [4] Metabolic dysfunction-associated steatotic liver disease in adults
    不详
    NATURE REVIEWS DISEASE PRIMERS, 2025, 11 (01):
  • [5] Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
    Castillo-Nunez, Yulino
    Almeda-Valdes, Paloma
    Gonzalez-Galvez, Guillermo
    Arechavaleta-Granell, Maria del Rosario
    CURRENT DIABETES REPORTS, 2024, 24 (07) : 158 - 166
  • [6] Metabolic dysfunction-associated steatotic liver disease in adults
    Huang, Daniel Q.
    Wong, Vincent W. S.
    Rinella, Mary E.
    Boursier, Jerome
    Lazarus, Jeffrey V.
    Yki-Jarvinen, Hannele
    Loomba, Rohit
    NATURE REVIEWS DISEASE PRIMERS, 2025, 11 (01):
  • [7] Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Orfanidou, Myrsini
    Polyzos, Stergios A.
    MEDICINA-LITHUANIA, 2025, 61 (01):
  • [8] Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Stefan, Norbert
    Roden, Michael
    DIABETOLOGIE UND STOFFWECHSEL, 2024, 19 : S290 - S296
  • [9] Metabolic dysfunction-associated steatotic liver disease in children
    Goyal, Nidhi P.
    Xanthakos, Stavra
    Schwimmer, Jeffrey B.
    GUT, 2025,
  • [10] Menopause and metabolic dysfunction-associated steatotic liver disease
    Polyzos, Stergios A.
    Goulis, Dimitrios G.
    MATURITAS, 2024, 186